UF Biostatistician at the Forefront of Groundbreaking Childhood Leukemia Drug Trial
A clinical trial co-designed by UF researcher found that adding blinatumomab to chemotherapy significantly reduced relapse risk in children with acute lymphoblastic leukemia, marking a major breakthrough in treatment.
Adding one drug to a chemotherapy regimen for children with acute lymphoblastic lymphoma decreased risk of relapse by about two-thirds, according to a study designed in part by John Kairalla, Ph.D., the senior statistician on the clinical trial and research associate professor and associate program director of the Children’s Oncology Group Statistics and Data Center in the College of Public Health and Health Professions’ Department of Biostatistics.
Read more about UF Biostatistician at the Forefront of Groundbreaking Childhood Leukemia Drug Trial.